Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NUSINERSEN vs OCRELIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

NUSINERSEN vs OCRELIZUMAB: Safety Overview

Metric NUSINERSEN OCRELIZUMAB
Total FAERS Reports 7,043 56,186
Deaths Reported 747 1,406
Death Rate 10.6% 2.5%
Hospitalizations 2,188 10,364
Average Patient Age 17.1 yrs 47.2 yrs
% Female Patients 50.1% 72.5%
FDA Approval Date Dec 23, 2016 N/A
Manufacturer Biogen Inc. Genentech, Inc.
Route INTRATHECAL INTRAVENOUS
Marketing Status Prescription Prescription